Form 4: Gilead Sciences Director Exercises Options and Sells Shares
SEC Form 4 Filing
Gilead Sciences director Jeffrey Bluestone exercised stock options and sold shares on November 26, 2024.
Summary
- On November 26, 2024, Jeffrey Bluestone, a director at Gilead Sciences, exercised non-qualified stock options to acquire 5,879 shares at $61.17 and 4,121 shares at $61.35.
- Following the exercise of these options, Mr. Bluestone sold 6,788 shares of common stock at an average price of $91.3901.
- After these transactions, Mr. Bluestone directly owns 8,920 shares of Gilead Sciences common stock and 11,730 non-qualified stock options.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing insider trading activity. It does not contain any information that would be considered positive or negative for the company's outlook.
Industry Context
This is a routine filing related to insider trading activity. It is common for directors and officers to exercise stock options and sell shares, and these transactions are closely monitored by regulators.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, such as Gilead Sciences, and are required by the SEC to ensure transparency in insider trading.
- The reported transactions are typical for directors who receive stock options as part of their compensation.
- Similar filings can be seen from directors and officers at other large pharmaceutical companies such as Pfizer, AbbVie, and Johnson & Johnson.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the sale of shares by a director.
- The information is relevant to shareholders who monitor insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 12/08/2020 | Start date for vesting of 25% of the shares subject to one of the options every three months. |
| 05/05/2022 | Grant date of the second stock option, which vested immediately. |
| 11/26/2024 | Date of the stock option exercises and share sale. |
| 11/27/2024 | Date of the filing of the Form 4. |
| 12/08/2030 | Expiration date of the first stock option. |
| 05/05/2032 | Expiration date of the second stock option. |
Keywords
Gilead Sciences, stock options, insider trading, Form 4, share sale, Jeffrey Bluestone, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.